(Q34620545)

English

Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

object named as

Clement Chung

1

1 reference

ORCID Public Data File 2021

author name string

Matthew Christianson

2

1 reference

Europe PubMed Central

3 August 2017

publication date

14 March 2013

1 reference

Europe PubMed Central

3 August 2017

Journal of Oncology Pharmacy Practice

1 reference

Europe PubMed Central

3 August 2017

20

1 reference

Europe PubMed Central

3 August 2017

1

1 reference

Europe PubMed Central

3 August 2017

11-28

1 reference

Europe PubMed Central

3 August 2017

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Validation of analytic methods for biomarkers used in drug development

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Genomics and the continuum of cancer care

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

CYP2D6 and tamoxifen: DNA matters in breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Systematic review of microsatellite instability and colorectal cancer prognosis

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Predicting fluorouracil toxicity: can we finally do it?

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression*.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Genomic index of sensitivity to endocrine therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Emerging targeted therapies for breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Everolimus: targeted therapy on the horizon for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Expression of epidermal growth factor receptor (EGF-R) in human lung tumours

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

The emerging role of biomarkers in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Crizotinib in the treatment of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Anaplastic large cell lymphoma, ALK-positive

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Antiangiogenic cancer therapy

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Challenges for patient selection with VEGF inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1177%2F1078155212474047

21 January 2018

Identifiers

10.1177/1078155212474047

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34620545&oldid=1635594048"